For clinicians, GLP-1based therapy has joined the toolkit for obesity in a way that demands attention and responsible use
It contains three patented, plant-based ingredients, each with its own small clinical study behind it: Eriomin (lemon bioflavonoids): shown to slightly increase natural GLP-1 levels in people with elevated blood sugar [1] Supresa (saffron extract): linked to reduced snacking in mildly overweight women, although some studies found no significant effects on food cravings [2][3] Morosil (red orange extract): found to support mild fat loss over 12 weeks [4] All three ingredients are studied independently , not as a combined formula
In the only direct evaluation of brain insulin resistance in PD, insulin signaling abnormalities were identified in the dorsolateral prefrontal and posterior parietal cortex of those with cognitive impairment, but not in those who were cognitively normal [72]
Retatrutide is currently an investigational triple-agonist medication being studied for obesity and metabolic health
These medications significantly slow gastric emptying, prolonging the sensation of fullness after meals and reducing appetite through central mechanisms in the hypothalamus
If you experienced severe vomiting, chronic nausea, dangerous dehydration, or stomach paralysis after using Ozempic or Wegovy, you may have grounds for legal action
